Cargando…

Combining onabotulinumtoxin A with a CGRP antagonist for chronic migraine prophylaxis: where do we stand?

Detalles Bibliográficos
Autor principal:	Pellesi, Lanfranco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pain Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641512/ https://www.ncbi.nlm.nih.gov/pubmed/37965209 http://dx.doi.org/10.3389/fpain.2023.1292994

Ejemplares similares

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
por: Smirnoff, Liza
Publicado: (2022)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

Perioperative Pain Management in Patients Undergoing Total Hip Arthroplasty: Where Do We Currently Stand?
por: Tsinaslanidis, Georgios, et al.
Publicado: (2020)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

Algometer Assessment of Pressure Pain Threshold After Onabotulinumtoxin-A and Physical Therapy Treatments in Patients With Chronic Migraine: An Observational Study
por: Deodato, Manuela, et al.
Publicado: (2022)

EHMTI-0105. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine
por: Cernuda-Morollón, E, et al.
Publicado: (2014)

Where do we stand with antithrombotic prophylaxis in patients with COVID-19?
por: Ciavarella, Alessandro, et al.
Publicado: (2020)

Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2017)

From Where We've Come to Where We Need to Go: Physiotherapy Management of Chronic Whiplash-Associated Disorder
por: Dickson, Cameron, et al.
Publicado: (2022)

Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
por: Scuteri, Damiana, et al.
Publicado: (2022)

Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2018)

Preclinical orofacial pain assays and measures and chronic primary orofacial pain research: where we are and where we need to go
por: Sadighparvar, Shirin, et al.
Publicado: (2023)

Where Do We Stand?
Publicado: (1891)

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
por: Favoni, Valentina, et al.
Publicado: (2019)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Antibiotic Prophylaxis for Children with Primary Vesicoureteral Reflux: Where Do We Stand Today?
por: Costers, Michiel, et al.
Publicado: (2008)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment
por: Guerzoni, Simona, et al.
Publicado: (2016)

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
por: Correale, Michele, et al.
Publicado: (2018)

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
por: Mechtler, Laszlo, et al.
Publicado: (2022)

Topical Pramoxine in Chronic Pruritus: Where do We Stand?
por: Agarwal, Akash, et al.
Publicado: (2021)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study
por: Pellesi, Lanfranco, et al.
Publicado: (2022)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
por: Charleston, Larry, et al.
Publicado: (2023)

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy
por: Holland, Philip R., et al.
Publicado: (2018)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Triptans and CGRP blockade – impact on the cranial vasculature
por: Benemei, Silvia, et al.
Publicado: (2017)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019)

Laser accelerators : where do we stand
por: Lawson, J D
Publicado: (1985)

Renormalization schemes: where do we stand?
por: Ward, B F L
Publicado: (1990)

Barrett's Esophagus: Where Do We Stand?
por: Al Madi, Majid A.
Publicado: (2009)

Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012)

LHC Access - Where do we Stand
por: Ninin, P, et al.
Publicado: (2006)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mp1i2rqqvcoreco7g7bl3o3icr